Interpreting Overall Survival and CNS Outcomes in EGFR Mutated Metastatic Non-Small Cell Lung Cancer
Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases.
Eric K. Singhi, MD
Advertisement
Articles by Eric K. Singhi, MD
Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population
2
FDA Grants Approval to Teclistamab Combo in RRMM
3
Why is the Incidence of Colorectal Cancer Rising in Young Patients?
4
Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer
5